LifeStance Health Foundation Partners with the American Foundation for Suicide Prevention to Advance Mental Health Research
LifeStance Health Foundation has renewed its partnership with the American Foundation for Suicide Prevention (AFSP), committing $100,000 to support clinical research aimed at advancing suicide prevention strategies. This renewed collaboration builds on a successful inaugural year where LifeStance contributed over $170,000 to AFSP's initiatives. The partnership emphasizes the critical need for continued research to address the urgent public health crisis of suicide, which claimed 48,824 lives in 2024.
LifeStance Health Foundation Renews Partnership with the American Foundation for Suicide Prevention to Advance Mental Health Research
LifeStance Health Foundation has renewed its partnership with the American Foundation for Suicide Prevention (AFSP), committing $100,000 to support clinical research aimed at advancing suicide prevention strategies. This renewed collaboration builds on their inaugural year, where LifeStance teammates and the Foundation contributed over $170,000 to AFSP initiatives. The partnership emphasizes the urgent need for research to improve understanding and prevention of suicide, especially given statistics showing over 48,000 deaths by suicide in 2024.
Lifestance Health Group stock hits 52-week high at 12.85 USD
Lifestance Health Group Inc. (LFST) stock hit a new 52-week high of $12.85, currently trading at $12.67, with a market capitalization of $4.72 billion. This surge reflects a 131.03% increase over the past year, driven by strong investor confidence and the company's robust Q2 2026 results. The mental health services provider reported a 26% revenue growth, a 94% rise in adjusted EBITDA, and exceeded analyst expectations, leading to raised full-year guidance.
Lifestance Health Group stock hits 52-week high at 12.85 USD
Lifestance Health Group Inc. (LFST) stock recently hit a 52-week high of $12.85, currently trading at $12.67 with a market capitalization of $4.72 billion. The company has seen a 131.03% increase in its stock over the past year and reported strong Q2 2026 results, surpassing analyst expectations with adjusted earnings of $0.06 per share and revenue of $435.35 million. This performance highlights the company's growth trajectory and operational strength in the mental health services sector.
Lifestance Health Group stock hits 52-week high at 12.85 USD
Lifestance Health Group (LFST) has reached a new 52-week high of $12.85, reflecting a 131.03% increase over the past year. This milestone follows impressive Q2 2026 results, where the company surpassed Wall Street expectations with doubled adjusted earnings, strong revenue growth, and a significant rise in adjusted EBITDA. The company attributes its success to productivity gains, payer contracting, and specialty services, leading to raised full-year guidance.
LifeStance Reaches Settlement in Data Privacy Lawsuit Involving 1 Million Patients
LifeStance Health has agreed to a $3 million settlement in a class-action lawsuit concerning data privacy. The lawsuit, brought by former patients, alleged that the outpatient mental health provider improperly shared identifiable patient data with Meta and Google using third-party tracking pixels on its website between March 2020 and April 2023. As part of the settlement, LifeStance must cease using such pixels and has stated its commitment to patient privacy and HIPAA compliance, while denying the allegations.
$3.02M LifeStance Health Group website tracking class action settlement
LifeStance Health Group has agreed to a $3.02 million class action settlement to resolve claims that it violated patients' privacy rights by using tracking pixels on its website. These pixels allegedly allowed third parties to collect sensitive patient information without consent, violating HIPAA and the Arizona Consumer Fraud Act. Eligible class members, divided into two subclasses based on their interaction with LifeStance's online booking tool, can receive a cash payment, with claims due by September 29, 2026.
Why LifeStance Health Group (LFST) Is Up 5.5% After Profitable Quarter, Higher Guidance And New Buyback
LifeStance Health Group (LFST) reported a profitable second quarter in 2026, with revenue of US$435.35 million and net income of US$23.61 million, a turnaround from a previous net loss. The company also raised its full-year 2026 revenue guidance to US$1.69 billion to US$1.73 billion and announced a new US$100 million share repurchase program after completing a prior one. This positive news, including the swing to profitability and continued capital returns, contributed to a 5.5% increase in its stock price.
Lifestance Health Q2 Call Highlights Profitable Growth
Lifestance Health Group's Q2 earnings call revealed strong growth and expanding profitability, with revenue jumping 26% year-over-year to $435 million and adjusted EBITDA nearly doubling to $66 million. The company raised its full-year revenue and adjusted EBITDA guidance, driven by increased visits, improved pricing, and disciplined cost management. Despite short-term headwinds from investments in technology and clinician compensation, Lifestance Health is focused on long-term growth through specialty services expansion and strategic acquisitions.
LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Average Recommendation of "Moderate Buy" from Analysts
Analysts have given LifeStance Health Group (NASDAQ:LFST) a consensus "Moderate Buy" rating, with an average 12-month price target of $12.13. The company recently surpassed quarterly earnings expectations, reporting an EPS of $0.06 against an estimated $0.03 and revenues of $435.35 million, a 26.1% year-over-year increase. Despite strong institutional ownership (85.5%), insiders have sold approximately $155 million worth of stock in the past 90 days.
LifeStance Health Group (NASDAQ:LFST) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded LifeStance Health Group (NASDAQ:LFST) from "buy" to "strong-buy" after the company exceeded Q2 earnings and revenue expectations. Despite this upgrade and a "Moderate Buy" consensus from other analysts, insiders have recently sold a significant amount of shares. The stock opened near its 52-week high, reflecting investor interest following strong financial performance.
LifeStance Health director Teresa DeLuca sells $249,993 in shares By Investing.com
LifeStance Health Group director Teresa DeLuca sold 20,441 shares of the company's common stock for $249,993 on August 13, 2026, with the shares trading near their 52-week high after a significant gain. Despite this sale, management has been actively buying back shares, though InvestingPro's Fair Value analysis suggests the stock is slightly overvalued. The company recently exceeded Q2 2026 earnings expectations, reporting strong revenue growth and increased adjusted EBITDA.
LifeStance Health Surpasses Q2 Earnings Expectations Driven by Clinician Growth
LifeStance Health significantly exceeded Q2 earnings expectations, reporting $435.4 million in revenue and an adjusted EPS of $0.11, driven by a 26.1% year-over-year growth and improved operational efficiency. The company raised its full-year guidance for both revenue and EBITDA, reflecting strong management confidence. This success is largely attributed to its expanding clinician base, now over 8,500, and the effective adoption of digital workflow tools in the rapidly growing mental health market.
LifeStance Health Group (NASDAQ:LFST) Given New $13.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has raised its price target for LifeStance Health Group (NASDAQ:LFST) to $13.00 from $9.00, while maintaining a "neutral" rating. This new target implies a potential upside of 2.48% from the stock's previous close. The company recently reported strong quarterly earnings, with $0.06 EPS against an expected $0.03, and revenue of $435.35 million, marking a 26.1% year-over-year increase, despite significant insider stock sales totaling approximately $155 million over the past three months.
LifeStance Health Group, Inc. SEC Filing (Aug 13, 2026)
This article reports on a Form 144 SEC filing by LifeStance Health Group, Inc. (LFST) on August 13, 2026. The filing indicates a proposed sale of 20,441 shares of common stock with an aggregate market value of $249,993.43 by an unnamed person through Fidelity Brokerage Services LLC, originating from restricted stock vesting on June 1, 2025. The document details the filer and issuer information required by the SEC.
5 Insightful Analyst Questions From LifeStance Health Group’s Q2 Earnings Call
LifeStance Health Group (LFST) exceeded Q2 earnings expectations with strong clinician productivity and specialty service expansion, prompting a raised full-year guidance. Analysts questioned management on productivity gains, revenue per visit drivers, EHR rollout, M&A strategy, and sequential EBITDA guidance, receiving insights into the company's operational improvements and future growth plans. Upcoming quarters will focus on specialty service rollout, EHR execution, and continued clinician recruitment.
LifeStance Health Group (NASDAQ:LFST) Major Shareholder Tpg Gp A, Llc Sells 13,643,207 Shares
Major shareholder Tpg Gp A, Llc sold over 13.6 million shares of LifeStance Health Group (NASDAQ:LFST) for approximately $144.9 million, reducing their stake by 12.21%. This transaction follows LifeStance's strong quarterly performance, which saw an EPS beat and 26.1% year-over-year revenue growth, pushing the stock near its 52-week high with a "Moderate Buy" consensus rating from analysts. Despite a COO share sale, the company exhibits positive sentiment from analyst upgrades and a new 52-week high.
Lisa Miller Sells 47,912 Shares of LifeStance Health Group (NASDAQ:LFST) Stock
Lisa Miller, COO of LifeStance Health Group (NASDAQ:LFST), sold 47,912 shares of the company's stock for approximately $519,845, reducing her stake by 14.55%. This transaction followed a strong quarterly earnings report where the company beat EPS estimates and saw a 26.1% increase in revenue, leading to a 6.3% rise in stock price. Analysts maintain a "Moderate Buy" consensus for LFST.
LifeStance CTO Vukasin Paunovich sells $481,674 in stock
LifeStance Health Group's CTO, Vukasin Paunovich, sold 44,394 shares worth $481,674 on August 10, 2026. This sale occurred after the stock surged 147% over the past year, trading 13% higher than the sale price. The company recently reported strong Q2 2026 financial results, exceeding analyst expectations and raising its full-year guidance.
LifeStance Health Group (LFST) Is Up 12.1% After Profit Turn, Higher Guidance And New Buyback Program
LifeStance Health Group (LFST) reported strong second-quarter results with higher sales and a move to net profitability, leading to a 12.1% increase in its stock. The company also raised its 2026 revenue outlook to about US$1.71 billion, completed a US$97.19 million share repurchase, and authorized a new buyback program of up to US$100 million. These actions reflect management's confidence in scaling operations and returning capital to shareholders, despite potential valuation risks due to rapid share price appreciation and a high earnings multiple.
LifeStance Health Group Inc (LFST) Shares Fall 3.4% -- GF Value Says Still Overvalued
LifeStance Health Group Inc (LFST) shares dropped 3.4% to $11.50, but according to GuruFocus' GF Value, the stock is still 35.8% overvalued with a GF Value of $8.47. The company's GF Score is 55/100, indicating average performance with strong financial strength but poor profitability and growth. Significant insider selling of $289.8 million in the last three months suggests caution for potential investors.
LifeStance Health (LFST) holder files to sell 500,000 common shares via Fidelity
A holder of LifeStance Health (LFST) common stock has filed a Form 144 to sell up to 500,000 shares through Fidelity Brokerage Services LLC, with an aggregate market value of over $5.7 million. These shares primarily originate from restricted stock vesting events tied to compensation in March 2025. The filing provides transparency regarding the potential sale relative to the 382 million shares outstanding.
Summit Partners group (LFST) discloses 6.10% LifeStance Health ownership in 13G/A
A group of Summit Partners-affiliated investment funds has filed an amended Schedule 13G, reporting a passive beneficial ownership of 6.10% in LifeStance Health Group, Inc. (LFST). This stake amounts to 23,310,115 shares of common stock out of 382,055,609 shares outstanding as of July 29, 2026. The filing details the distribution of shares among various Summit funds and clarifies that investment and voting decisions are managed by a three-person investment committee at Summit Partners, L.P.
LifeStance Health Group, Inc. (LFST) Soars to 52-Week High, Time to Cash Out?
LifeStance Health Group (LFST) has reached a new 52-week high, with shares up 9.4% in the past month and 69% year-to-date. The company has consistently beaten earnings estimates, reporting 600% EPS growth for the current fiscal year. Despite concerns about its high valuation metrics compared to its industry peers, the stock holds a Zacks Rank #2 (Buy) due to favorable earnings estimate revisions, suggesting potential for further gains.
One in Three Women Unaware Perimenopause Can Cause Mental Symptoms
A LifeStance Health survey found that one in three women are unaware that perimenopause can cause mental health symptoms, despite a majority experiencing severe anxiety and depression. The survey revealed that 83% of women who tried therapy found it helpful, and nearly half believe mental healthcare should be a standard part of perimenopause care. This highlights a significant knowledge gap and a demand for integrated mental health support during this life stage, which currently costs the U.S. economy billions in lost productivity.
LifeStance Survey Finds Women Want Mental Healthcare Built Into Perimenopause and Menopause Care
A new survey by LifeStance Health reveals that a significant number of women are unaware of the mental health impact of perimenopause, with one in three not knowing it can cause anxiety, depression, and mood changes. The survey highlights that while most women find mental healthcare helpful, nearly half believe it should be a standard component of perimenopause care. This indicates a strong demand for integrated mental health services during these life stages, especially given the substantial economic costs associated with unaddressed menopause symptoms.
LifeStance Health Group (LFST) holder cites pre-IPO shares in planned resale
Citadel Securities LLC has filed a Form 144 notice regarding the planned resale of 21,572 shares of LifeStance Health Group (LFST) common stock. These shares were acquired through pre-IPO transactions on June 10, 2021. The filing also notes that Citadel sold 1,273 LifeStance shares on NASDAQ for $13,519.26 within the past three months.
LifeStance Health (LFST) Form 144 shows planned sale of 1.09M shares
LifeStance Health Group Inc. has filed a Form 144 indicating a proposed resale of 1,088,162 shares of its common stock, with an aggregate market value of $11,556,280.44. The shares are scheduled to be sold on or after August 10, 2026, on NASDAQ through Citadel Securities LLC. This filing notes that the seller acquired 18,446,106 equity interests in LifeStance during a pre-IPO transaction on June 10, 2021.
LifeStance Health Group (LFST) investor plans NASDAQ sale of 12,165 shares
A stockholder of LifeStance Health Group Inc. (LFST) plans to sell 12,165 shares of common stock on NASDAQ through Citadel Securities LLC. The proposed sale, valued at $129,192.30, is scheduled for August 10, 2026. The seller had previously acquired 206,219 equity interests in LifeStance in a pre-IPO transaction on June 10, 2021.
LifeStance Health Group, Inc. SEC Filing (Aug 10, 2026)
This article reports on a Form 144 SEC filing by LifeStance Health Group, Inc. (LFST) on August 10, 2026. The filing indicates a proposed sale of 44,394 shares of common stock acquired through restricted stock vesting on March 9, 2026, with an aggregate market value of $481,674.90. Fidelity Brokerage Services LLC is listed as the broker for the sale on NASDAQ.
LifeStance Health Group Surges 13.0% Amid Sector-Wide Rally
LifeStance Health Group (NASDAQ:LFST) surged 13.0% to $12.25, leading a broad rally in the medical care facilities sector. This sector-wide movement, which also saw RDNT climb 6.8% and BLLN gain 4.7%, indicates investor enthusiasm potentially driven by optimism about industry fundamentals or macroeconomic tailwinds. The robust trading activity for LifeStance, coupled with recent constructive analyst activity, suggests a significant shift in sentiment towards healthcare services stocks.
LifeStance Health Group (NASDAQ:LFST) Reaches New 1-Year High After Analyst Upgrade
LifeStance Health Group (NASDAQ:LFST) shares hit a new 52-week high after BTIG Research raised its price target from $15 to $16, maintaining a buy rating. The company exceeded quarterly expectations with adjusted earnings of $0.06 per share and revenue up 26.1% year-over-year. Despite favorable analyst sentiment, insiders have sold over 7.6 million shares worth approximately $62.9 million in the last three months.
Lifestance Health Group Inc stock hits 52-week high at 11.77 USD
Lifestance Health Group Inc (LFST) stock reached a 52-week high of $11.77, trading near its peak valuation with a market capitalization of $4.35 billion. Despite being considered slightly overvalued by InvestingPro, the stock has seen a 148% increase over the past year and reported strong Q2 2026 financial results with significant revenue growth and adjusted EBITDA increase.
LifeStance Health gains as Hedgeye adds as new long idea
LifeStance Health (LFST) shares surged by 14% after Hedgeye identified it as a new long idea, projecting a potential upside of 32-60%. Hedgeye analyst Tom Tobin noted that the company's core business is outperforming consensus expectations across all three key revenue drivers.
Renaissance Technologies LLC Has $5.10 Million Stake in LifeStance Health Group, Inc. $LFST
Renaissance Technologies LLC significantly increased its stake in LifeStance Health Group (LFST) by 92.5% in the first quarter, now holding 800,500 shares valued at $5.1 million. LifeStance reported strong Q2 results, with revenue up 26.1% year-over-year and adjusted earnings beating estimates, leading to a raised 2026 outlook and a new $100 million share-repurchase program. Despite a "Moderate Buy" analyst rating, there has been notable insider selling, with 7.6 million shares sold by insiders in the last three months.
LifeStance Health Group, Inc. Q2 2026: Revenue $435.4M, EPS $0.06— 10-Q Summary
LifeStance Health Group, Inc. reported strong Q2 2026 results, with revenue increasing to $435.4M from $345.3M year-over-year, and net income turning profitable at $23.6M compared to a loss of $3.8M in Q2 2025. Diluted EPS reached $0.06, up from $(0.01) in the prior-year quarter. This growth was driven by an increase in clinicians and patient visits, supported by their hybrid care model and strengthened referral networks.
LifeStance Health Group, Inc. Stock 12‑Month Price Target Raised to $12.6, Implies 22% Upside
LifeStance Health Group, Inc.'s average price target has been increased from $12 to $12.6 by 10 analysts, suggesting a 22% potential upside from its Aug. 5 closing price. The consensus rating for the stock remains a "Buy" across 11 analysts, with 9 recommending Buy and 2 recommending Hold.
LifeStance Health Group Q2 2026 Earnings Call Transcript
LifeStance Health Group (NASDAQ: LFST) reported a strong second quarter in 2026, exceeding expectations with 26% revenue growth, 19% increase in visits, and a near doubling of Adjusted EBITDA to $66 million. The company raised its full-year 2026 guidance, projecting revenue of $1.685 billion-$1.725 billion and Adjusted EBITDA of $215 million-$235 million, driven by clinician additions, improved productivity, and expansion of specialty services. LifeStance is also investing in technology, including a new EHR system for 2027, and exploring strategic tuck-in acquisitions to expand its geographic footprint, while emphasizing its commitment to clinical excellence and measurable patient outcomes.
LifeStance Health Doubles Earnings as It Prioritizes Tuck-In M&A
LifeStance Health Group (Nasdaq: LFST) nearly doubled its adjusted profits in the second quarter, driven by increased payer reimbursement, higher clinician productivity, and steady clinician headcount growth. The company reported a 94% increase in adjusted EBITDA to $66 million and a 26% rise in revenue to $435.4 million. LifeStance Health plans to continue focusing on "small tuck-in" M&A for strategic growth and entering new geographies, while raising its predicted revenue and adjusted EBITDA for 2026.
LifeStance Health Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LFST) 2026-08-06
LifeStance Health Group, Inc. (LFST) released its Q2 2026 earnings call presentation, reporting an EPS of $0.11, beating estimates by $0.03. The company also announced revenue of $435.35M, an increase of 26.08% year-over-year, surpassing expectations by $20.82M. This article provides access to the slide deck published in conjunction with the earnings call.
LifeStance Health Group Q2 Earnings Call Highlights
LifeStance Health Group (NASDAQ:LFST) reported strong second-quarter results, exceeding expectations with a 26% year-over-year revenue increase to $435 million and a nearly doubled adjusted EBITDA of $66 million. The company raised its full-year guidance for revenue and adjusted EBITDA, indicating strong growth and profitability. LifeStance plans to reinvest earnings into patient acquisition, technology, clinician support, and specialty services, while also pursuing strategic tuck-in acquisitions for geographic expansion.
LifeStance Health Group (NASDAQ:LFST) Reports Strong Q2 CY2026, Guides for Strong Full-Year Sales
LifeStance Health Group (NASDAQ:LFST) reported strong Q2 CY2026 results, beating Wall Street's revenue and EPS expectations with sales up 26.1% year-on-year. The company also raised its full-year revenue and EBITDA guidance, demonstrating significant operating leverage and increased profitability. Following these positive results, the stock traded up 3%.
LifeStance Health surges on strong Q2 beat and raised outlook
LifeStance Health Group (NASDAQ:LFST) reported stronger-than-expected second-quarter results and raised its full-year guidance, leading to an 11.7% surge in shares. The company posted adjusted EPS of $0.06 and revenue of $435.4 million, exceeding analyst estimates, and saw a significant increase in net income and adjusted EBITDA. LifeStance also announced a new $100 million share repurchase program, replacing a previous one.
LifeStance Health Group (LFST) Tops Q2 Earnings and Revenue Estimates
LifeStance Health Group (LFST) reported Q2 earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.03, and revenues of $435.35 million, surpassing estimates by 5.08%. The company has consistently beaten both EPS and revenue estimates over the past four quarters. Despite outperforming the market year-to-date, its current Zacks Rank #3 (Hold) suggests it will perform in line with the market in the near future.
LifeStance Health Group (NASDAQ:LFST) Reports Strong Q2 CY2026, Guides for Strong Full-Year Sales
LifeStance Health Group (NASDAQ:LFST) reported strong Q2 CY2026 results, surpassing Wall Street's revenue and EPS expectations. The company's sales rose 26.1% year-on-year to $435.4 million, and its GAAP profit was $0.06 per share. LifeStance also raised its full-year revenue and EBITDA guidance, indicating a positive outlook for the company's financial performance.
LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
LifeStance Health Group, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing by 26% to $435.4 million and net income reaching $23.6 million. The company raised its full-year 2026 outlook for revenue, Center Margin, and Adjusted EBITDA, and approved a new $100 million share repurchase program. These positive results were driven by growth in clinician base, increased visit volumes, and improved clinician productivity.
Earnings Flash (LFST) LifeStance Health Posts Q2 EPS $0.06, vs. FactSet Est of $0.04
LifeStance Health Group (LFST) reported its Q2 EPS at $0.06, surpassing the FactSet estimate of $0.04. The company also announced an equity buyback of $100 million worth of its shares and raised its earnings guidance for the fiscal year 2026, alongside providing Q3 2026 earnings guidance. The company, which swung to a Q2 profit with rising revenue, expects Q3 revenue between $420.0M and $440.0M and full-year 2026 revenue between $1.69B and $1.73B.
LifeStance board approves up to $100 million share buyback
LifeStance Health Group (Nasdaq: LFST) reported strong Q2 2026 financial results with revenue up 26% year-over-year to $435.4 million and net income turning positive at $23.6 million. The company raised its full-year 2026 guidance for revenue, Center Margin, and Adjusted EBITDA. Additionally, LifeStance announced its board approved a new $100 million share repurchase program, replacing a previous authorization.
What To Expect From LifeStance Health Group’s (LFST) Q2 Earnings
LifeStance Health Group (LFST) is set to announce its Q2 earnings this Thursday. The company exceeded revenue expectations last quarter, reporting $403.5 million, and analysts anticipate a 20.1% year-on-year revenue growth for the upcoming quarter. Despite past revenue misses, peer performance suggests a mixed outlook, with LFST's stock currently down 6.7% over the last month.
What To Expect From LifeStance Health Group’s (LFST) Q2 Earnings
LifeStance Health Group (LFST) is set to announce its Q2 earnings this Thursday morning. The company previously exceeded revenue expectations in Q1, reporting $403.5 million, and analysts anticipate a 20.1% year-on-year revenue growth for Q2. While peers like DaVita and Centene have reported mixed results, LFST's stock is down 6.7% over the last month, trading below its average analyst price target.
